-transparent.png){kind=logo}
2',3'-Dideoxycytidinene (ddeCyd), the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine (ddCyd) is, like ddCyd itself, a potent and selective inhibitor of HTLV-III/LAV in vitro. This conclusion is based on the relatively high ratio of effective antiviral dose (0.3 microM) versus cell growth inhibitory concentration (20-35 microM) and the lack of any appreciable inhibitory activity against a series of non-oncogenic RNA and DNA viruses. Both compounds were considerably more inhibitory to human lymphoid cell lines than human nonlymphoid or murine cell lines. They were highly dependent on prior activation by deoxycytidine kinase to exert their anti-HTLV-III/LAV and cytostatic effects. In contrast with ddCyd, ddeCyd lost part of its anti-retrovirus effect upon prolonged incubation (10 days) with the virus-infected cells in culture.
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
February 1987,
Clinical chemistry,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
December 1985,
Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
January 1986,
Sangre,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
March 1986,
Deutsche medizinische Wochenschrift (1946),
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
May 1986,
Deutsche medizinische Wochenschrift (1946),
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
January 1986,
Rivista di emoterapia ed immunoematologia,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
December 2001,
Organic letters,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
March 1986,
Medicina clinica,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
January 1986,
Nordisk medicin,
J Balzarini, and
R Pauwels, and
P Herdewijn, and
E De Clercq, and
D A Cooney, and
G J Kang, and
M Dalal, and
D G Johns, and
S Broder
January 1993,
Drug metabolism and disposition: the biological fate of chemicals,
